Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology. FDA-backed ...
RCKT Developing Another Gene-Therapy for Heart Diseases Besides RP-A601, RCKT is developing another AAV-based gene therapy candidate, RP-A701, for treating BAG3-associated dilated cardiomyopathy (BAG3 ...
Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as cardiomyocytes—and the heart's limited regenerative capacity often lead to ...
Hosted on MSN
Specific human gene can help the heart repair itself from heart attack or heart failureA naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...
Rocket Pharmaceuticals RCKT announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adeno-associated virus (AAV)-based gene therapy, ...
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...
Medley Therapeutics (formerly YAP Therapeutics) has dosed the first cohort (n=3) with YAP101 in the Phase 1 SALVADOR-HF trial at The Texas Heart Institute at Baylor College of Medicine in the Baylor ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the publication in peer-reviewed journal Nature Medicine of 12-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results